The Student Movement Volume 107 Issue 19: A Weekend to Remember: AUnited Showcases Cultural Diversity

HUMANS Andrews Students Discuss Feminism, Interviewed by: Grace No Honors Scholars and Undergraduate Research Poster Symposium: Meet the Researchers, Nora Martin Public vs Private Schooling?, Interviewed by: Anna Pak ARTS & ENTERTAINMENT Creatives on Campus: Women\u27s History Month, Gio Lee See My World: AU Composers\u27 Recital, Aiko J. Ayala Rios Sonnets Reimagined: English 430 Collage Projects, Grace No NEWS Cultural Clubs Wow During Preview Showcase, Andrew Francis Head in the Clouds: The AUnited Cultural Gala, Alannah Tjhatra Honors Scholars and Undergraduate Research Poster Symposium 2023, Nora Martin IDEAS A Kinda Brief History of Feminism, Reagan McCain Bee Kind!, Gabriela Francisco The History of Saint Patrick\u27s Day, Katie Davis PULSE The Dorms: What Would You Change?, Interviewed by: Lexie Dunham The President-Elect: Viewpoint on Diversity, Wambui Karanja LAST WORD What I Would Tell My Freshman Self, Kayla-Hope Brunohttps://digitalcommons.andrews.edu/sm-107/1018/thumbnail.jp

The Student Movement Volume 107 Issue 5: Barkada Means Friendship: Andrews Embraces Fall and Filipino Culture

HUMANS AIFA Celebrates Barkada, Interviewed by: Sara Hamstra AU Student\u27s Thoughts About Autumn, Interviewed by: Kavya Mohanram Meet Joshua Deonarine, AUSA Financial VP, Interviewed by: Gloria Oh Women in STEM Interview: Emily Rusnak, Interviewed by: Lauren Kim ARTS & ENTERTAINMENT Box Factory for the Arts, Ysabelle Fernando Creatives on Campus: Filipino American History Month Edition, Ceiry Flores The Old Warhorse: Wind Symphony\u27s Saturday Concert, Skylor Stark NEWS Edsel Adap\u27s Story: How AFIA Came to Be, Sara Hamstra Learning Traditional Filipino Dance with AFIA, Ceiry Flores Andrews Opens New Career Center!, Gloria Oh IDEAS Be Your Own Bastion for Fashion, Shania Watts Seasonal Depression at AU, Kayla-Hope Bruno Worldbuilder\u27s Disease, T Bruggemann PULSE FALLing in Love With Autumn, Lexie Dunham Filipino-American HISTORY Month, Charisse Lapuebla In Loving Memory of the Gazebo Smoothies, Elizabeth Dovich LAST WORD Existential Dread, Alannah Tjhatrahttps://digitalcommons.andrews.edu/sm-107/1004/thumbnail.jp

The Student Movement Volume 107 Issue 11: Have a Merry Christmas! XOXO, The Student Movement

HUMANS Coping with Finals, Solana Campbell Meet Jea Erazo, AUSA Public Relations Officer. Interviewed by: Caryn Cruz Remembering Sharon Dudgeon, Grace No Women in STEM: Olivia Joyce, Interviewed by: Gloria Oh ARTS & ENTERTAINMENT Football Sunday, Nathaniel Reid, Skylor Stark Student Picks: Christmas Classics, Ysabelle Fernando NEWS AFIA x MLS Christmas Party, Ceiry Flores Boycotts and Bans at the Qatar World Cup, Hannah Cruse In Loving Memory of Seth Williams, Gloria Oh IDEAS How Do We Address Queer Violence?, Alexander J. Hess Is Reality Really Real When You Aren\u27t Really Looking?, Alexander Navarro Reflecting on Christmas Traditions, Rachel Ingram-Clay The New Era of Book Bans, Elizabeth Getahun Why is Everyone so Happy During Christmastime?, Kayla-Hope Bruno PULSE Bon Appétit and the Threat to Cultural Autonomy, Wambui Karanja It\u27s OrnaMEANT to be a Wonderful Christmastime, Lexie Dunham It\u27s the Most Stressful Time of the Year, Reagan McCain Qatar Controversy: The Shadow Behind the World Cup, Melissa Moore Reflections on the Semester and Plans for Break, Elizabeth Dovich LAST WORD A Student Movement Christmas, The Student Movement Staffhttps://digitalcommons.andrews.edu/sm-107/1010/thumbnail.jp

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc